Up 180% in a year, is it too late to buy Pro Medicus shares?

The question lingers.

| More on:
Cropped shot of an attractive young female scientist working on her computer in the laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pro Medicus Ltd (ASX: PME) shares continue their meteoric rise, having recently nudged fresh new highs this week.

The healthcare stock is currently trading at $249.55 apiece, up an astonishing 180% over the past 12 months, having soared 32% this past month alone.

With such electrifying gains, the question we have now is twofold: Does this ASX healthcare darling still have room to run? Or has the ship already left for port? Let's see what the experts think.

Created with Highcharts 11.4.3Pro Medicus PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

Why Pro Medicus shares are flying high

Pro Medicus is in the healthcare imaging technology business. So its profits aren't really that correlated to the broader business cycle. Would you skip an essential MRI in a recession? Exactly.

This year, Pro Medicus shares have been on a tear thanks to the tasty ingredient mix of record-breaking financial performance and massive contract wins.

Pro Medicus announced this week that it secured a ten-year, $330 million deal with US-based Trinity Health. This is the company's largest customer to date.

This follows a string of successes in the North American market, where its Visage 7 Enterprise Imaging Platform is becoming the go-to solution for radiologists.

The Trinity Health contract will see Pro Medicus' fully cloud-based system implemented across 93 hospitals, 107 continuing care locations, and 142 urgent care centres.

In total, this is 342 locations across each of these mediums.

Pro Medicus also reported a good set of FY24 results. Revenues were up 29% over the year, clipping to $161.5 million at the top line with 36% growth in net profit.

As such, every dollar of sales produced $1.24 in net profit, which is not a bad ratio to work with at all.

Is there still upside for Pro Medicus shares?

This is the big question for Pro Medicus shares. While the share price has skyrocketed, according to CommSec, the general consensus on the stock right now is a hold.

The rating is made up of three buys, four holds and one sell.

Goldman Sachs is one of those sitting around the fire in camp buy. The broker says the company's leadership in 'cloud-native imaging' and its growing pipeline of large contracts are bullish points.

In our view, PME is well positioned into FY25 given a full-year benefit of some large and high profile contracts, in addition to the accelerating frequency and size of new contract wins.

We see PME's software Visage 7 as an industry-leading solution with two distinct advantages relative to peers — speed and cloud capabilities — that have influenced the choice of PACS vendor. Given this, PME is benefiting from an industry network effect as more hospitals move to modern systems.

The broker also says moving into factors like artificial intelligence (AI) and cardiology could be the accelerant to Pro Medicus' growth fire.

Consensus projects earnings to expand by 25% per year out to FY26, which is a terrific business result.

Even still, the stock trades are more than 290x trailing earnings at the time of writing. In my view, this should be factored into the debate.

Foolish takeaway

Pro Medicus shares have delivered incredible returns this year. But the company's strong fundamentals and vast growth runway suggest there may still be upside for patient investors.

Even still, consensus rates it a hold.

As is always the case with managing investments, a long-term view is critical. Don't get caught up in the market's short-term machinations.

That way, you can participate in the good fortune of stocks like Pro Medicus, which has increased from $5 per share in 2017 to its current price, nearly 50x growth in value.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »